GHK-Cu · research summary

A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.

Archives of internal medicine research · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Systematic review of literature published between 2005 and 2026
“This systematic review synthesizes the body of GHK-Cu literature published between 2005 and 2026, mapped against the PRISMA framework.”

Subjects

In vitro cells, ex vivo skin, rodent and non-rodent animals, and humans
“Studies were stratified by study model (in vitro, ex vivo, in vivo rodent, in vivo non-rodent, and human) so that comparator therapies could be matched on equivalent footing.”

Sample size

64 records retained for qualitative synthesis
“after deduplication and screening, 64 records were retained for qualitative synthesis.”

Duration

Literature published between 2005 and 2026
“This systematic review synthesizes the body of GHK-Cu literature published between 2005 and 2026, mapped against the PRISMA framework.”

Reported findings

Preclinical evidence is mechanistically coherent, but human clinical evidence is limited to small trials and lacks adequately powered randomized controlled trials for microneedle delivery.
“The synthesis confirms a deep, mechanistically coherent body of preclinical evidence and reveals a defined evidence gap: well-designed human trials of GHK-Cu delivered via microneedle or microneedle-adjacent platforms (dissolvable patches, hollow microneedle arrays, dermaroller-assisted serums) are needed to translate the strong cellular and animal data into validated clinical practice.”
GHK-Cu modulates gene expression in over 30 percent of measured human genes, shifting patterns toward more physiologic states.
“Connectivity Map analyses suggests that GHK-Cu exposure alters gene expression in over 30 percent of measured human genes by at least 50 percent, with most of these changes associated with a shift from diseased toward more physiologic expression patterns [1].”

Source: PubMed 42787770 · DOI 10.26502/aimr.0255 · all study summaries

Reported findings

Preclinical evidence is mechanistically coherent, but human clinical evidence is limited to small trials and lacks adequately powered randomized controlled trials for microneedle delivery.

“The synthesis confirms a deep, mechanistically coherent body of preclinical evidence and reveals a defined evidence gap: well-designed human trials of GHK-Cu delivered via microneedle or microneedle-adjacent platforms (dissolvable patches, hollow microneedle arrays, dermaroller-assisted serums) are needed to translate the strong cellular and animal data into validated clinical practice.”

GHK-Cu modulates gene expression in over 30 percent of measured human genes, shifting patterns toward more physiologic states.

“Connectivity Map analyses suggests that GHK-Cu exposure alters gene expression in over 30 percent of measured human genes by at least 50 percent, with most of these changes associated with a shift from diseased toward more physiologic expression patterns [1].”